Drug Profile

SLV 310

Latest Information Update: 10 Jul 2007

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Solvay
Class Antipsychotics; Phthalimides; Pyridines
Mechanism of Action Dopamine D2 receptor antagonists; Serotonin uptake inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

06 Apr 2004 Solvay and Wyeth Pharmaceuticals formed a worldwide agreement to co-develop and co-commercialise SLV 310
28 Jan 2003 Phase-II clinical trials in Psychotic disorders (unspecified route)
31 Jul 2000 Phase-I clinical trials for Psychotic disorders (Unknown route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com